254 related articles for article (PubMed ID: 29363545)
1. Downregulation of Membrane Trafficking Proteins and Lactate Conditioning Determine Loss of Dendritic Cell Function in Lung Cancer.
Caronni N; Simoncello F; Stafetta F; Guarnaccia C; Ruiz-Moreno JS; Opitz B; Galli T; Proux-Gillardeaux V; Benvenuti F
Cancer Res; 2018 Apr; 78(7):1685-1699. PubMed ID: 29363545
[TBL] [Abstract][Full Text] [Related]
2. HDAC9 deficiency promotes tumor progression by decreasing the CD8
Ning Y; Ding J; Sun X; Xie Y; Su M; Ma C; Pan J; Chen J; Jiang H; Qi C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554611
[TBL] [Abstract][Full Text] [Related]
3. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
4. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
5. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
6. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
7. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer.
Ugolini A; Tyurin VA; Tyurina YY; Tcyganov EN; Donthireddy L; Kagan VE; Gabrilovich DI; Veglia F
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584791
[TBL] [Abstract][Full Text] [Related]
8. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
9. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
10. Dysfunction of antigen processing and presentation by dendritic cells in cancer.
Bandola-Simon J; Roche PA
Mol Immunol; 2019 Sep; 113():31-37. PubMed ID: 29628265
[TBL] [Abstract][Full Text] [Related]
11. Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.
Lorenzi S; Mattei F; Sistigu A; Bracci L; Spadaro F; Sanchez M; Spada M; Belardelli F; Gabriele L; Schiavoni G
J Immunol; 2011 May; 186(9):5142-50. PubMed ID: 21441457
[TBL] [Abstract][Full Text] [Related]
12. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
Cioca DP; Deak E; Cioca F; Paunescu V
J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
[TBL] [Abstract][Full Text] [Related]
14. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
[TBL] [Abstract][Full Text] [Related]
15. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
[TBL] [Abstract][Full Text] [Related]
16. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
17. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
18. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
19. TLR3-Mediated CD8+ Dendritic Cell Activation Is Coupled with Establishment of a Cell-Intrinsic Antiviral State.
Széles L; Meissner F; Dunand-Sauthier I; Thelemann C; Hersch M; Singovski S; Haller S; Gobet F; Fuertes Marraco SA; Mann M; Garcin D; Acha-Orbea H; Reith W
J Immunol; 2015 Aug; 195(3):1025-33. PubMed ID: 26101320
[TBL] [Abstract][Full Text] [Related]
20. Appropriate timing of CD40 ligation for RNA-Pulsed DCs to induce antitumor immunity.
Miura S; Kagamu H; Tanaka H; Yoshizawa H; Gejyo F
Scand J Immunol; 2008 Apr; 67(4):385-91. PubMed ID: 18282232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
